<DOC>
	<DOC>NCT00360490</DOC>
	<brief_summary>The purpose of this study is to determine whether the levonorgestrel-releasing intrauterine system is effective in decreasing menstrual blood loss.</brief_summary>
	<brief_title>Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)</brief_title>
	<detailed_description>Acronyms in the Adverse Event Section: - IUCD Intrauterine Contraceptive Device - MedDRA Medical Dictionary for Regulatory Activities This study has previously been posted by Berlex, Inc. and Schering AG, Germany. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc., Schering AG Germany has been renamed to Bayer HealthCare AG, Germany.</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Women who have &gt;/= 80 mL blood loss during their menstrual cycles and desire contraception Post menopausal menstrual cycle &lt; 21 days or &gt; 35 days Pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Idiopathic Menorrhagia</keyword>
</DOC>